Scandion Oncology Q3 2022: Back to the basics

Research Update

2022-11-16

11:36

Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruited the first of up to 36 patients to its phase II CORIST part 3 dose-finding arm. We adjust our estimates and fair value range to reflect current capital market conditions.

CB

JU

Christian Binder

Johan Unnerus

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.